Savvas Papageorgiou’s Post

𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! A recent study used our TRC research chemicals (TRC-M325750) and ATCC cancer cell lines to identify a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/B0cD6m 🌟Our extensive cancer portfolio can help from target identification to drug development and manufacturing. We provide industry-leading life science tools - from biologically active small molecules to cellular models! Explore https://okt.to/Klq6g0 and https://okt.to/UW9d4m #LungCancer #ProductCitation #oncologyresearch #ResearchChemicals

In this article we demonstrate for the first time the oncogenic role of the microRNA miR1305 in the disruption of autophagy-controlled cancer cell dormancy. Our study demonstrates how inflammatory cytokines (IL-6) can awaken the dormant tumor and cause recurrence by inducing the production of miRNA 1305 which then turns off autophagy. Interestingly, the anti-cancer nutraceutical Resveratrol can inhibit this effect and keep cancer cells in a dormant state. Thanks to my collaborators for such a nice work.

An excellent 𝑵𝒂𝒕𝒖𝒓𝒆 𝑪𝒐𝒎𝒎𝒖𝒏𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 paper by Youya Nakazawa et al. describing yet another innovative ADC structure. In the paper the authors show preclinical efficacy in a pancreatic cancer model of an ADC composed of a BET protein-degrader 'warhead' conjugated to an anti-CEACAM6 antibody. https://lnkd.in/eUK_P294

Check out the latest article from Labiotech.eu, where Mural CEO Caroline J Loew, PhD, shares how our novel protein engineering approach may be able to harness native IL-2’s potency while overcoming the challenges historically seen with IL-2 therapies.   Read the article below ⬇️ #immunotherapy #cytokines #proteinengineering #oncology 

#CDK4/6 inhibitors show anticancer activity in certain human malignancies, but their application to other tumor types and intrinsic resistance mechanisms are still unclear. #MYC amplification confers resistance to CDK4/6 inhibitors in bladder, prostate, and #breastcancer cancer cells, and a compound that degrades MYC, A80.2HCl, restores sensitivity of MYC high-expressing cancer cells to CDK4/6i. #cancerresearch #drugdiscovery https://lnkd.in/eMuJf9-5

💡【Exciting New #OriginalArticle Alert! 】 🎬 Evaluation of molecular effects associated with apoptosis, tumour progression, angiogenesis and metastasis by a novel combination of drugs with ormeloxifene in triple negative breast cancer cells 📖 This study reveals the efficacy of Orm + comb as more significant than the clinically used tamoxifen (Tam). The study elucidates the promising novelty of the combination as a potential chemotherapeutic intervention for mitigating the aggressiveness of triple negative breast cancer and it addresses the intrinsic resistance caused by single drug treatments. 👨⚕️ Authors: Shehna Sharaf, Sreelekshmi S, Saikant Regidi, Abi Santhosh Aprem, Rajmohan Gopimohan, Lakshmi S * 📚 This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer #Ormeloxifene, #Metastasis, #BreastCancer, #Tumour 🏃♂️ Welcome to read, forward and share the article!  https://lnkd.in/grKAvz4V

We present HYL001, a potent TGF-beta signaling inibitor. A few years ago, we and others discovered that high TGF-beta signaling in tumours impedes effective T-cell infiltration rendering immune checkpoint blockade therapy (anti- PD1, anti PD-L1) ineffective (Tauriello et al., Nature 2018; Mariathasen et al., Nature 2018). TGF-beta inhibitors override the immune-excluded phenotype and allow effective immunotherapy in pre-clinical models of metastatic colorectal cancer. This discovery was followed by similar findings in a number of other tumour types, and currently this combination is being tested in a number of clinical trials (Tauriello et al., Nat Rev Cancer, 2022). However, clinical development of TGF-beta inhibitors is proving to be diffciult as to date, there is no single agent approved by regulatory agencies. We are hopeful that HYL001 may provide a potent inhibition of TGF-beta signaling with a realticvely safe profile, based on previous studies with the structurally related compound galunisertib (LY2157299) https://lnkd.in/d-nirXPi

KRAS, once considered undruggable, is now the target of two approved drugs, including those targeting the G12C mutation. Using PROTAC technology, researchers have developed ACBI3, a molecule that selectively degrades 13 out of the 17 most common KRAS mutations, including KRASG12D. This approach leads to sustained inhibition of cancer cell growth. The study demonstrates that KRAS degradation is more effective and durable than inhibition alone, offering a promising new therapeutic strategy for KRAS-driven cancers, potentially benefiting patients with a range of KRAS mutations. https://lnkd.in/e8FHiRcy #oncology; #cancer; #Kras

Great work! Important study highlighting role of CEACAM1/TIM-3 mediated immune exhaustion in cancer progression. Combined use of tamoxifen and anti-CEACAM1/TIM-3 blockade is suggested to improve outcome of immune checkpoint blockade therapy. These results are well aligned with our recent publication, wherein we highlighted the role of CEACAM1 in cancer resistance. https://lnkd.in/eA5Ckp3y

Lantern Pharma's expansion of its Phase II Harmonic trial into Japan and Taiwan marks a pivotal step in lung cancer treatment for never-smokers. This trial assesses the efficacy of LP-300 combined with chemotherapy, focusing on non-small cell lung cancer (NSCLC). Key Points: ▪️ Targeted Treatment - Investigating LP-300 in populations with high rates of specific genetic mutations. ▪️ Global Impact - Aiming to gather vital data quickly to push forward LP-300's development. Considerations: ▪️ How will this trial influence global approaches to cancer treatment? ▪️ What strategies should be adopted to meet the needs of diverse patient populations? #CancerResearch #ClinicalTrials #PersonalizedMedicine